505(b)(2) generic drug development refers to a regulatory pathway in the United States where a generic drug seeks approval based partly on the safety and efficacy data of a previously approved reference product. This pathway allows for streamlined approval processes for modifications to existing drugs, such as changes in dosage form, route of administration, or active ingredient.